Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 3/20 | 0.54 |
| ▸ | GSK3B | P49841 | 2/20 | 0.52 |
| ▸ | DKK1 | O94907 | 1/20 | 0.52 |
| ▸ | IKBKB | O14920 | 6/20 | 0.51 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.48 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 4/20 | 0.47 |
| ▸ | CDK2 | P24941 | 4/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.47 |
| ▸ | CDK9 | P50750 | 3/20 | 0.47 |
| ▸ | CDK7 | P50613 | 1/20 | 0.47 |
| ▸ | CCNH | P51946 | 1/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.47 |
| ▸ | CCND3 | P30281 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1632940 | 0.93 | PTK2 (0.56) | SYKGSK3BDKK1IKBKBMAP4K1 | |
| SCHEMBL1633311 | 0.89 | CA2 (0.56) | SYKGSK3BDKK1IKBKBMAP4K1 | |
| SCHEMBL1634189 | 0.88 | MAPK8 (0.56) | SYKGSK3BDKK1IKBKBMAP4K1 | |
| SCHEMBL1632246 | 0.87 | SYK (0.50) | SYKGSK3BDKK1IKBKBMAP4K1 | |
| SCHEMBL1632476 | 0.86 | MAP3K5 (0.57) | SYKGSK3BDKK1IKBKBMAP4K1 | |
| SCHEMBL1633521 | 0.86 | BRAF (0.54) | SYKGSK3BDKK1IKBKBCDK1 | |
| SCHEMBL1634389 | 0.85 | IKBKB (0.49) | SYKGSK3BDKK1IKBKBCA2 | |
| SCHEMBL13498325 | 0.84 | IKBKB (0.54) | SYKGSK3BDKK1IKBKBCA2 | |
| SCHEMBL1631337 | 0.84 | CA1 (0.48) | SYKGSK3BDKK1IKBKBCA2 | |
| SCHEMBL1632143 | 0.83 | MAP4K1 (0.58) | GSK3BDKK1IKBKBMAP4K1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | SYK 4204/4885GSK3B 453/4885DKK1 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.